Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Milestone Achieved

4 Jan 2007 07:00

ViaLogy PLC04 January 2007 ViaLogy plc ("ViaLogy" or "the Company") Milestone Achieved Completion of Key Milestone on Multi-parallax Exploitation ("MPEX") ElectronicEye(TM)Program with Boeing Phantom Works LONDON, Jan 2 -- ViaLogy plc (LSE: VIY), a leading innovator of real-timenetwork-centric signal processing platforms for sensor-intensive applications,announced today that it has successfully completed the Critical Design Review("CDR") Milestone on the Multi-parallax Exploitation ("MPEX") Electronic EyeTMProgram with Boeing Phantom Works ("Boeing") in Huntington Beach, CA, USA. The Electronic Eye(TM)program was initiated in direct response to emergingprecision detection requirements in next-generation missile detection anddefense systems (seekers) and panoramic airspace surveillance platforms. Underthe joint program with Boeing, ViaLogy's core signal processing technology -Quantum Resonance Interferometry ("QRI") - is providing the basic engine forpowering the silicon electronic-eye based on vision constructs found in insectsand reptiles. Vialogy has a patent pending on the MPEX Electronic Eye(TM)and itsapplications. Currently, most advanced vision systems are limited to only stereo vision with asingle parallax based on the co-registration of frames from two eyes, allowingonly a scan of the horizon. In contrast, MPEX Electronic Eye(TM)is exploitingmultiple parallaxes to achieve panoramic or 360-degree viewing capability andthree dimensional perception using multiple, overlapping fields-of-view. Thisconstruction dramatically increases the probability of target detection andlocalization. Dr. Edward McCullough, Principal Scientist in advanced aero analysis at BoeingPhantom Works, commented: "I am very excited by ViaLogy's rapid progress andnovel approach on the MPEX Electronic Eye(TM) Researchers have been studying thecomputational architectures, functions, mechanisms, and principles of visualperception underlying biological systems for over three decades to find ways toimplement them. We have specific near-term and long-term interests in thistechnology to support our defense, homeland security and space program needs." ViaLogy's Chief Technology Officer, Dr. Sandeep Gulati said: "We are buildingupon seminal work conducted by Dr. McCullough and his team in the area ofbiomimetic-based advanced autonomy for future planetary rovers and spaceoperations. Our core technology provides a near-term opportunity for overcomingsome of the fundamental information processing and system engineering challengesin implementing multi-parallax construction to address practicalomni-directional surveillance applications. MPEX has been developed as aplatform technology in its own right and we are now making good progress inadapting it for specific applications." ViaLogy's initial MPEX Electronic Eye(TM)applications are geared to detection ofvery fast moving targets such as in missile interceptors, deployment on fastmoving ground vehicles and airborne platforms such as UAVs (unmanned aerialvehicles), and omni-directional tower mounts for border surveillance andcritical infrastructure security. Commenting on the achievement of this milestone, ViaLogy's CEO, Michael Kelly,said: "MPEX is very well aligned with the ViaLogy business model. We can applyour unique expertise and sensor-agnostic signal processing technology tocommercial off-the-shelf hardware and sensors to deliver enhanced performance ata fraction of the cost of comparable systems especially designed for militaryapplications." Next steps in the Boeing collaboration include a demonstration of the use ofMPEX Electronic Eye(TM)engineering for detection of ground-based border intrusionevents, and an aerial payload for low altitude UAVs. Successful operationaldemonstration of the proprietary MPEX technology could lead to its use in anumber of future defense and homeland security programs. For further information please contact: ViaLogyMichael Kelly, CEO - US +1 626 296 6337Terry Bond, Chairman - UK & Europe +44 (0)20 2869 7014 Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor (intensive) applications. ViaLogy is currently deployingand designing computational systems, powered by its patented technologies, forapplications in life sciences, public safety and security, surveillance, defenseand geoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied by such forward-looking statements. Such factors include generaleconomic and business conditions, the ability to acquire and develop specificprojects, the ability to fund operations and changes in consumer and businessconsumption habits and other factors over which ViaLogy has little or nocontrol. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.